Evolus (EOLS) reported $297M in revenue for fiscal 2025, +11.6% year on year. That ranks #2486 by revenue among 2853 SEC filers and #249 in Healthcare. It posted a net loss of −$51.6M for the same year. The fiscal 2025 balance sheet shows $226M in total assets, $53.8M in cash and $146M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $297M | +11.6% | FY20252025-12-31 |
| Gross profitGrossProfit | $197M | +8.1% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$32.7M | +$1.7M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$51.6M | −$1.2M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$42.3M | −$24.3M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $3.4M | +133.8% | FY20252025-12-31 |
| Total assetsAssets | $226M | −2.9% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | −$23.1M | −$28.6M | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $53.8M | −38.1% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $146M | +20.2% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $73.1M | −$10.7M | Open → |
| Q2 20262026-06-30 | $84.1M | −$8.1M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Evolus, Inc.
- Ticker
- EOLS
- Exchange
- Nasdaq
- SIC classification
- Pharmaceutical Preparations (2834)
- Fiscal year end
- 12-31
- CIK
- 0001570562
Filings
- 10-QAug 5, 2026Open filing →
- 10-QMay 4, 2026Open filing →
- 10-KMar 3, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Procept BioroboticsPRCT | $308M | −$95,572 |
| BilliontooneBLLN | $305M | $7.5M |
| Skinhealth SystemsSKIN | $301M | −$9.5M |
| EvolusEOLS | $297M | −$51.6M |
| Ironwood PharmaceuticalsIRWD | $296M | $24.0M |
| Rigel PharmaceuticalsRIGL | $294M | $367M |
| Xeris BiopharmaXERS | $292M | $554,000 |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Evolus — Key figures |url=https://companiesranked.com/en/company/evolus |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Evolus — Key figures. CompaniesRanked. https://companiesranked.com/en/company/evolusBibTeX
@misc{companiesranked-en-company-evolus-2026,
author = {{CompaniesRanked}},
title = {{Evolus — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/evolus}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-014001 · March 3, 2026
{{cite web |title=Evolus — Key figures — 10-K (0001628280-26-014001) |url=https://www.sec.gov/Archives/edgar/data/1570562/000162828026014001/eols-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-03}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.